Richard M. Fleming, PhD, MD, JD

In 1994, Dr. Fleming presented to the American Heart Association his "theory" that cardiovascular disease was due to inflammation.  What was theory in 1994 has become well known fact for decades and was highlighted in 2004,with a feature on ABC's 20/20 News.

Patent # 9566037 was issued to  Dr. Fleming on February 14, 2017.

The Fleming Method patent (FMTVDM) covers ALL methods and devices able to measure metabolic and regional blood flow differences.  This breakthrough made it possible to differentiate functionality of tissue, tissue types as well as non-tissue, and the measurement of treatment response using all isotopes, enhancing agents and devices capable of detecting and measuring isotopes.

Developing technology that disrupts the methods of conventional medicine is not always welcomed.  Especially when that technology would half the revenue a $20 billion nuclear isotope industry. When physicians bring innovation to medicine, complaints to medical boards often follow along with court cases, which is why it's called, "Disruptive Technology."

Read About It

His knowledge and patent enables previously undetectable inflammation to be seen and measured with levels of accuracy not found in most common scanning and technologies or devices.

The real genius behind nuclear imaging is that it provides a physiologic measure of what is going on in the body.  This can be used to differentiate benign versus cancerous cells, to determine how cancer will respond to treatment, or to find hidden diseases that appears non-existent.

With the current SARS-CoV-2 pandemic, this technology could prove to be an integral tool to determine areas of viral attack and associated immune response leading to potential
inflammatory thrombosis (ITR).

Areas of Expertise -

Cardiologist, Nuclear Cardiologist

Certified in Positron Emission Tomography (PET)

Juris Prudence Doctor of Law

Researcher

Inventor

Author